Information Provided By: 
Fly News Breaks for June 20, 2017
CLVS
Jun 20, 2017 | 07:41 EDT
Credit Suisse analyst Alethia Young said she views the ARIEL3 trial data as a "major de-risking event" for Clovis that increased her conviction that Rubraca can have a meaningful market opportunity in the PARP ovarian cancer space. Young, who sees M&A and full ARIEL3 data at ESMO in September as the next important catalysts for Clovis, raised her price target on the stock to $107 from $88 and keeps an Outperform rating on the name.
News For CLVS From the Last 2 Days
There are no results for your query CLVS
